

# Yot Teerawattananon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8242567/publications.pdf>

Version: 2024-02-01

178  
papers

8,637  
citations

101543

36  
h-index

51608

86  
g-index

184  
all docs

184  
docs citations

184  
times ranked

13346  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of population-based screening for diabetes and hypertension in India: an economic modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e65-e73.	10.0	14
2	A systematic review of methodological approaches for evaluating real-world effectiveness of COVID-19 vaccines: Advising resource-constrained settings. <i>PLoS ONE</i> , 2022, 17, e0261930.	2.5	22
3	Recalibrating the notion of modelling for policymaking during pandemics. <i>Epidemics</i> , 2022, 38, 100552.	3.0	8
4	Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e057537.	1.9	4
5	A model-based study to estimate the health and economic impact of health technology assessment in Thailand. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, 1-14.	0.5	5
6	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>International Journal of Technology Assessment in Health Care</i> , 2022, 38, .	0.5	8
7	What Can We Learn From Others to Develop a Regional Centre for Infectious Diseases in ASEAN? Comment on "Operationalising Regional Cooperation for Infectious Disease Control: A Scoping Review of Regional Disease Control Bodies and Networks". <i>International Journal of Health Policy and Management</i> , 2022, .	0.9	1
8	Designing and Implementing Deliberative Processes for Health Technology Assessment: A Good Practices Report of a Joint HTAi/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 869-886.	0.3	11
9	Dispelling the myths of providing dialysis in low- and middle-income countries. <i>Nature Reviews Nephrology</i> , 2021, 17, 11-12.	9.6	7
10	Evaluating traditional and complementary medicines: Where do we go from here?. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e45.	0.5	3
11	A landscape analysis of health technology assessment capacity in the Association of South-East Asian Nations Region. <i>Health Research Policy and Systems</i> , 2021, 19, 19.	2.8	15
12	Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India. <i>BMJ Open</i> , 2021, 11, e042280.	1.9	5
13	Developing a Thai national critical care allocation guideline during the COVID-19 pandemic: a rapid review and stakeholder consultation. <i>Health Research Policy and Systems</i> , 2021, 19, 47.	2.8	17
14	Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. <i>Vaccine</i> , 2021, 39, 1402-1414.	3.8	3
15	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. <i>Lancet</i> , The, 2021, 397, 1023-1034.	13.7	885
16	Addressing Challenges in Health Technology Assessment Institutionalization for Furtherance of Universal Health Coverage Through South-South Knowledge Exchange: Lessons From Bhutan, Kenya, Thailand, and Zambia. <i>Value in Health Regional Issues</i> , 2021, 24, 187-192.	1.2	15
17	Research collaboration is needed to inform quarantine policies for health-care workers. <i>Lancet</i> , The, 2021, 397, 2334.	13.7	3
18	Retrospective secondary data analysis to identify high-cost users in inpatient department of hospitals in Thailand, a middle-income country with universal healthcare coverage. <i>BMJ Open</i> , 2021, 11, e047330.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Avoiding Trouble Ahead: Lessons Learned and Suggestions for Economic Evaluations of COVID-19 Vaccines. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 463-472.	2.1	5
20	Assessing the performance of health technology assessment (HTA) agencies: developing a multi-country, multi-stakeholder, and multi-dimensional framework to explore mechanisms of impact. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 37.	1.5	5
21	An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. <i>Frontiers in Public Health</i> , 2021, 9, 722927.	2.7	49
22	Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making. <i>Cost Effectiveness and Resource Allocation</i> , 2021, 19, 62.	1.5	14
23	A protocol for a systematic literature review of economic evaluation studies of interventions to address antimicrobial resistance. <i>Systematic Reviews</i> , 2021, 10, 242.	5.3	4
24	Protocol for the economic evaluation of COVID-19 pandemic response policies. <i>BMJ Open</i> , 2021, 11, e051503.	1.9	2
25	Using health technology assessment to set priority, inform target product profiles, and design clinical study for health innovation. <i>Technological Forecasting and Social Change</i> , 2021, 172, 121000.	11.6	11
26	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100221.	5.6	26
27	Tackling the 3 Big Challenges Confronting Health Technology Assessment Development in Asia: A Commentary. <i>Value in Health Regional Issues</i> , 2020, 21, 66-68.	1.2	9
28	Prioritizing critical-care resources in response to COVID-19: lessons from the development of Thailand's Triage protocol. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 540-544.	0.5	5
29	Institutionalizing Evidence-Informed Priority Setting for Universal Health Coverage: Lessons From Indonesia. <i>Inquiry (United States)</i> , 2020, 57, 004695802092492.	0.9	10
30	The physical activity at work (PAW) study protocol: a cluster randomised trial of a multicomponent short-break intervention to reduce sitting time and increase physical activity among office workers in Thailand. <i>BMC Public Health</i> , 2020, 20, 1332.	2.9	12
31	Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 474-480.	0.5	33
32	Cost-utility analysis of adjuvant chemotherapy after concurrent chemoradiation in patients with locally advanced cervical cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 873-881.	1.8	4
33	Growth and capacity for cost-effectiveness analysis in Africa. <i>Health Economics (United Kingdom)</i> , 2020, 29, 945-954.	1.7	34
34	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. <i>PLoS ONE</i> , 2020, 15, e0233950.	2.5	7
35	Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. <i>BMJ, The</i> , 2020, 368, m141.	6.0	25
36	To include or not include: renal dialysis policy in the era of universal health coverage. <i>BMJ, The</i> , 2020, 368, m82.	6.0	13

#	ARTICLE	IF	CITATIONS
37	Making pharmaceutical research and regulation work for women. <i>BMJ, The</i> , 2020, 371, m3808.	6.0	17
38	Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0242415.	2.5	35
39	Comparing 3 Approaches for Making Vaccine Adoption Decisions in Thailand. <i>International Journal of Health Policy and Management</i> , 2020, 9, 439-447.	0.9	4
40	Charging for the use of survey instruments on population health: the case of quality-adjusted life years. <i>Bulletin of the World Health Organization</i> , 2020, 98, 59-65.	3.3	3
41	What next after GDP-based cost-effectiveness thresholds?. <i>Gates Open Research</i> , 2020, 4, 176.	1.1	36
42	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. , 2020, 15, e0233950.		0
43	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. , 2020, 15, e0233950.		0
44	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. , 2020, 15, e0233950.		0
45	“It takes two to tango”: Bridging the gap between country need and vaccine product innovation. , 2020, 15, e0233950.		0
46	Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia. <i>BMC Health Services Research</i> , 2019, 19, 573.	2.2	3
47	Criteria Used for Priority-Setting for Public Health Resource Allocation in Low- and Middle-Income Countries: A Systematic Review. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 474-483.	0.5	22
48	Adjusting for Inflation and Currency Changes Within Health Economic Studies. <i>Value in Health</i> , 2019, 22, 1026-1032.	0.3	151
49	Cost-Effectiveness Analysis for Influenza Vaccination Coverage and Timing in Tropical and Subtropical Climate Settings: A Modeling Study. <i>Value in Health</i> , 2019, 22, 1345-1354.	0.3	16
50	Landscape analysis of health technology assessment (HTA): systems and practices in Asia. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 416-421.	0.5	17
51	From Design to Evaluation: Applications of Health Technology Assessment in Myanmar and Lessons for Low or Lower Middle-Income Countries. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 461-466.	0.5	7
52	Adherence to the iDSI reference case among published cost-per-DALY averted studies. <i>PLoS ONE</i> , 2019, 14, e0205633.	2.5	27
53	A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand. <i>BMC Ophthalmology</i> , 2019, 19, 82.	1.4	9
54	Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand. <i>Cost Effectiveness and Resource Allocation</i> , 2019, 17, 1.	1.5	13

#	ARTICLE	IF	CITATIONS
55	Disease Control Priorities Third Edition: Time to Put a Theory of Change Into Practice Comment on "Disease Control Priorities Third Edition Is Published: A Theory of Change Is Needed for Translating Evidence to Health Policy". <i>International Journal of Health Policy and Management</i> , 2019, 8, 132-135.	0.9	7
56	Essential medicines for universal health coverage. <i>Kazan Medical Journal</i> , 2019, 100, 4-111.	0.2	3
57	The Development of the Guide to Economic Analysis and Research (GEAR) Online Resource for Low- and Middle-Income Countries™ Health Economics Practitioners: A Commentary. <i>Value in Health</i> , 2018, 21, 569-572.	0.3	20
58	Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option. <i>Vaccine</i> , 2018, 36, 1757-1765.	3.8	17
59	Cost-utility analysis of the screening program for early oral cancer detection in Thailand. <i>PLoS ONE</i> , 2018, 13, e0207442.	2.5	7
60	Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India. <i>Health Research Policy and Systems</i> , 2018, 16, 115.	2.8	20
61	The EQ-5D-5L Valuation study in Thailand. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 551-558.	1.4	94
62	Incorporating economies of scale in the cost estimation in economic evaluation of PCV and HPV vaccination programmes in the Philippines: a game changer?. <i>Cost Effectiveness and Resource Allocation</i> , 2018, 16, 7.	1.5	3
63	Identifying priority technical and context-specific issues in improving the conduct, reporting and use of health economic evaluation in low- and middle-income countries. <i>Health Research Policy and Systems</i> , 2018, 16, 4.	2.8	21
64	Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. <i>Clinical Drug Investigation</i> , 2018, 38, 853-865.	2.2	10
65	Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. <i>PLoS ONE</i> , 2018, 13, e0193112.	2.5	7
66	An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities. <i>PLoS ONE</i> , 2018, 13, e0199318.	2.5	3
67	HISTORICAL DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF SUCCESS. <i>International Journal of Technology Assessment in Health Care</i> , 2018, 34, 260-266.	0.5	15
68	Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?. <i>F1000Research</i> , 2018, 7, 72.	1.6	13
69	Quality of life after great saphenous vein ablation in Thai patients with great saphenous vein reflux. <i>Asian Journal of Surgery</i> , 2017, 40, 295-300.	0.4	8
70	Essential medicines for universal health coverage. <i>Lancet</i> , The, 2017, 389, 403-476.	13.7	366
71	Institutionalising health technology assessment: establishing the Medical Technology Assessment Board in India. <i>BMJ Global Health</i> , 2017, 2, e000259.	4.7	50
72	Health Technology Assessment capacity development in low- and middle-income countries: Experiences from the international units of HITAP and NICE. <i>F1000Research</i> , 2017, 6, 2119.	1.6	62

#	ARTICLE	IF	CITATIONS
73	Economic evaluation of policy options for dialysis in end-stage renal disease patients under the universal health coverage in Indonesia. PLoS ONE, 2017, 12, e0177436.	2.5	37
74	How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries?. International Journal of Health Policy and Management, 2017, 6, 529-533.	0.9	5
75	Designing the Free Drugs List in Nepal. MDM Policy and Practice, 2017, 2, 238146831769176.	0.9	5
76	Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness". International Journal of Health Policy and Management, 2017, 6, 233-236.	0.9	28
77	Health financing lessons from Thailand for South Africa on the path towards universal health coverage. South African Medical Journal, 2016, 106, 533.	0.6	6
78	The influence of cost-per-DALY information in health prioritisation and desirable features for a registry: a survey of health policy experts in Vietnam, India and Bangladesh. Health Research Policy and Systems, 2016, 14, 86.	2.8	8
79	Improving quality of primary care through financial incentives: the case of Thailand. Journal of the Royal Society of Medicine, 2016, 109, 292-293.	2.0	2
80	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. Value in Health, 2016, 19, 921-928.	0.3	203
81	Vaccination program in a resource-limited setting: A case study in the Philippines. Vaccine, 2016, 34, 4814-4819.	3.8	12
82	Nationwide survey of nutritional management in an Asian upper-middle income developing country government hospitals: Combination of quantitative survey and focus group discussion. Clinical Nutrition ESPEN, 2016, 14, 24-30.	1.2	3
83	A Systematic Review of Economic Evaluation Methodologies Between Resource-Limited and Resource-Rich Countries: A Case of Rotavirus Vaccines. Applied Health Economics and Health Policy, 2016, 14, 659-672.	2.1	13
84	Development of a Health Screening Package Under the Universal Health Coverage: The Role of Health Technology Assessment. Health Economics (United Kingdom), 2016, 25, 162-178.	1.7	26
85	Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6. BMC Gastroenterology, 2016, 16, 91.	2.0	8
86	Maternal and child health voucher scheme in Myanmar: a review of early stage implementation. BMC Health Services Research, 2016, 16, 600.	2.2	9
87	Health Technology Assessment as a Priority-Setting Tool for Universal Health Coverage: The Call for Global Action at the Prince Mahidol Award Conference 2016. Pharmacoeconomics, 2016, 34, 1-3.	3.3	6
88	How to meet the demand for good quality renal dialysis as part of universal health coverage in resource-limited settings?. Health Research Policy and Systems, 2016, 14, 21.	2.8	29
89	An ex-ante economic evaluation of the Maternal and Child Health Voucher Scheme as a decision-making tool in Myanmar. Health Policy and Planning, 2016, 31, 482-492.	2.7	11
90	Role of priority setting in implementing universal health coverage. BMJ, The, 2016, 532, i244.	6.0	10

#	ARTICLE	IF	CITATIONS
91	One Step Back, Two Steps Forward: An Economic Evaluation of the PEN Program in Indonesia. <i>Health Systems and Reform</i> , 2016, 2, 84-98.	1.2	13
92	Foreword: Health Economic Evaluations in Low- and Middle-Income Countries: Methodological Issues and Challenges for Priority Setting. <i>Health Economics (United Kingdom)</i> , 2016, 25, 1-5.	1.7	31
93	Cost-utility and budget impact analysis of drug treatments in pulmonary arterial hypertension associated with congenital heart diseases in Thailand. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 525-536.	1.4	7
94	Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand. <i>Phlebology</i> , 2016, 31, 573-581.	1.2	10
95	Priority-setting for achieving universal health coverage. <i>Bulletin of the World Health Organization</i> , 2016, 94, 462-467.	3.3	108
96	EFFECTIVENESS OF DIAPERS AMONG PEOPLE WITH CHRONIC INCONTINENCE IN THAILAND. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 249-255.	0.5	5
97	Perceived barriers to utilise methadone maintenance therapy among male injection drug users in rural areas of southern Thailand. <i>Drug and Alcohol Review</i> , 2015, 34, 645-653.	2.1	12
98	Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development. <i>PLoS ONE</i> , 2015, 10, e0123853.	2.5	31
99	Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines. <i>PLoS ONE</i> , 2015, 10, e0131156.	2.5	36
100	An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand. <i>PLoS ONE</i> , 2015, 10, e0134782.	2.5	16
101	Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0145953.	2.5	60
102	Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 687-700.	1.4	8
103	Economic Evaluation of 3-Drug Antiretroviral Regimens for the Prevention of Mother-to-Child HIV Transmission in Thailand. <i>Asia-Pacific Journal of Public Health</i> , 2015, 27, NP866-NP876.	1.0	5
104	Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes. <i>Population Health Management</i> , 2015, 18, 265-271.	1.7	9
105	Seasonal Influenza Vaccination for Children in Thailand: A Cost-Effectiveness Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001829.	8.4	34
106	Mortality Attributable to Seasonal Influenza A and B Infections in Thailand, 2005-2009: A Longitudinal Study. <i>American Journal of Epidemiology</i> , 2015, 181, 898-907.	3.4	16
107	A learning experience from price negotiations for vaccines. <i>Vaccine</i> , 2015, 33, A11-A12.	3.8	20
108	A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines. <i>BMC Public Health</i> , 2015, 15, 730.	2.9	25



#	ARTICLE	IF	CITATIONS
109	Is diabetes and hypertension screening worthwhile in resource-limited settings? An economic evaluation based on a pilot of a Package of Essential Non-communicable disease interventions in Bhutan. <i>Health Policy and Planning</i> , 2015, 30, 1032-1043.	2.7	21
110	A cost-utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. <i>Rheumatology</i> , 2014, 53, 138-144.	1.9	18
111	Economic costs of obesity in Thailand: a retrospective cost-of-illness study. <i>BMC Health Services Research</i> , 2014, 14, 146.	2.2	33
112	Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand. <i>Clinical Therapeutics</i> , 2014, 36, 534-543.	2.5	15
113	The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , 2014, 108, 397-404.	0.9	60
114	A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand. <i>BMC Health Services Research</i> , 2014, 14, 170.	2.2	10
115	Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries. <i>Lancet Oncology</i> , The, 2014, 15, e119-e131.	10.7	124
116	A Cost-Utility Analysis Comparing Standard Axillary Lymph Node Dissection with Sentinel Lymph Node Biopsy in Patients with Early Stage Breast Cancer in Thailand. <i>Value in Health Regional Issues</i> , 2014, 3, 59-66.	1.2	10
117	Assessing the Accuracy and Feasibility of a Refractive Error Screening Program Conducted by School Teachers in Pre-Primary and Primary Schools in Thailand. <i>PLoS ONE</i> , 2014, 9, e96684.	2.5	20
118	Evidence-informed policy formulation: the case of the voucher scheme for maternal and child health in Myanmar. <i>WHO South-East Asia Journal of Public Health</i> , 2014, 3, 285.	0.7	5
119	Development and Validation of a Breast Cancer Risk Prediction Model for Thai Women: A Cross-Sectional Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6811-6817.	1.2	14
120	Advanced health biotechnologies in Thailand: redefining policy directions. <i>Journal of Translational Medicine</i> , 2013, 11, 1.	4.4	128
121	Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. <i>Epilepsia</i> , 2013, 54, 1628-1638.	5.1	73
122	Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?. <i>Vaccine</i> , 2013, 31, 2839-2847.	3.8	50
123	Risk Factors of Breast Cancer. <i>Asia-Pacific Journal of Public Health</i> , 2013, 25, 368-387.	1.0	135
124	Variation of health-related quality of life assessed by caregivers and patients affected by severe childhood infections. <i>BMC Pediatrics</i> , 2013, 13, 122.	1.7	31
125	Health technology assessment in universal health coverage. <i>Lancet</i> , The, 2013, 382, e48-e49.	13.7	38
126	Assessing key model parameters for economic evaluation of pandemic influenza interventions: the data source matters. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 59-63.	3.4	3



#	ARTICLE	IF	CITATIONS
127	Universal coverage of renal dialysis in Thailand: promise, progress, and prospects. <i>BMJ, The</i> , 2013, 346, f462-f462.	6.0	61
128	Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund. <i>Globalization and Health</i> , 2013, 9, 35.	4.9	14
129	Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 29.	1.9	62
130	Using health technology assessment for informing coverage decisions in Thailand. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 137-146.	1.4	60
131	Social values and health policy: a new international research programme. <i>Journal of Health Organization and Management</i> , 2012, 26, 285-292.	1.3	30
132	Efficiency or equity: value judgments in coverage decisions in Thailand. <i>Journal of Health Organization and Management</i> , 2012, 26, 331-342.	1.3	22
133	Economic Evaluation of Rehabilitation Services for Inpatients with Stroke in Thailand: A Prospective Cohort Study. <i>Value in Health Regional Issues</i> , 2012, 1, 29-35.	1.2	12
134	Lessons drawn from research utilization in the maternal iodine supplementation policy development in Thailand. <i>BMC Public Health</i> , 2012, 12, 391.	2.9	3
135	Evidence to Inform Decision Makers in Thailand: A Cost-Effectiveness Analysis of Screening and Treatment Strategies for Postmenopausal Osteoporosis. <i>Value in Health</i> , 2012, 15, S20-S28.	0.3	8
136	Impact of the Introduction of Government Use Licenses on the Drug Expenditure on Seven Medicines in Thailand. <i>Value in Health</i> , 2012, 15, S95-S99.	0.3	18
137	Multicriteria Decision Analysis for Including Health Interventions in the Universal Health Coverage Benefit Package in Thailand. <i>Value in Health</i> , 2012, 15, 961-970.	0.3	99
138	Health Related Quality of Life among Patients with Tuberculosis and HIV in Thailand. <i>PLoS ONE</i> , 2012, 7, e29775.	2.5	43
139	Systematic Review of Economic Evaluations of Preparedness Strategies and Interventions against Influenza Pandemics. <i>PLoS ONE</i> , 2012, 7, e30333.	2.5	54
140	The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand's pharmaceutical benefit package. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 361.	1.9	16
141	Risk prediction models of breast cancer: a systematic review of model performances. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 1-10.	2.5	106
142	Multi-criteria decision analysis for setting priorities on HIV/AIDS interventions in Thailand. <i>Health Research Policy and Systems</i> , 2012, 10, 6.	2.8	55
143	Priority-Setting Institutions in Health: Recommendations from a Center for Global Development Working Group. <i>Global Heart</i> , 2012, 7, 13.	2.3	70
144	Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand. <i>Pharmacoeconomics</i> , 2011, 29, 781-806.	3.3	51

#	ARTICLE	IF	CITATIONS
145	Is There a Role for Pharmacoeconomics in Developing Countries?. <i>Pharmacoeconomics</i> , 2011, 29, 433-435.	3.3	1
146	Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand. <i>BMC Public Health</i> , 2011, 11, 534.	2.9	18
147	Government use licenses in Thailand: an assessment of the health and economic impacts. <i>Globalization and Health</i> , 2011, 7, 28.	4.9	18
148	The economic costs of alcohol consumption in Thailand, 2006. <i>BMC Public Health</i> , 2010, 10, 323.	2.9	44
149	Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. <i>BMC Public Health</i> , 2010, 10, 401.	2.9	17
150	Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment. <i>BMC Health Services Research</i> , 2010, 10, 197.	2.2	37
151	A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand. <i>BMC Health Services Research</i> , 2010, 10, 209.	2.2	27
152	Scaling up cervical cancer screening in the midst of human papillomavirus vaccination advocacy in Thailand. <i>BMC Health Services Research</i> , 2010, 10, S5.	2.2	25
153	Provider-initiated HIV/AIDS counselling and testing at healthcare facilities in Thailand: a cluster-randomisation trial. <i>Journal of Development Effectiveness</i> , 2009, 1, 450-469.	0.8	3
154	Historical development of health technology assessment in Thailand. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 241-252.	0.5	49
155	The economic impact of alcohol consumption: a systematic review. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2009, 4, 20.	2.2	110
156	Using Economic Evaluation in Policy Decision-Making in Asian Countries: Mission Impossible or Mission Probable?. <i>Value in Health</i> , 2009, 12, S26-S30.	0.3	44
157	The Current Capacity and Future Development of Economic Evaluation for Policy Decision-Making: A Survey among Researchers and Decision-Makers in Thailand. <i>Value in Health</i> , 2009, 12, S31-S35.	0.3	25
158	Economic Impact on Health-Care Costs Related to Major Diseases Including HIV/AIDS due to Alcohol Drinking among Thai Populations. <i>Value in Health</i> , 2009, 12, S97-S100.	0.3	4
159	Strengthening Cost-Effectiveness Analysis in Thailand through the Establishment of the Health Intervention and Technology Assessment Program. <i>Pharmacoeconomics</i> , 2009, 27, 931-945.	3.3	47
160	Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. <i>Lancet</i> , The, 2009, 373, 2223-2233.	13.7	2,889
161	A Difficult Balancing Act: Policy Actors' Perspectives on Using Economic Evaluation to Inform Health-Care Coverage Decisions under the Universal Health Insurance Coverage Scheme in Thailand. <i>Value in Health</i> , 2008, 11, S52-S60.	0.3	37
162	Health-Care Systems and Pharmacoeconomic Research in Asia-Pacific Region. <i>Value in Health</i> , 2008, 11, S137-S155.	0.3	53

#	ARTICLE	IF	CITATIONS
163	The greatest happiness of the greatest number? Policy actors' perspectives on the limits of economic evaluation as a tool for informing health care coverage decisions in Thailand. BMC Health Services Research, 2008, 8, 197.	2.2	18
164	Making health technology assessment information available for decision making: the development of a Thai database. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2008, 91 Suppl 2, S8-10.	0.1	5
165	Thai health technology assessment guideline development. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2008, 91 Suppl 2, S11-5.	0.1	10
166	Measurement of clinical effects. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2008, 91 Suppl 2, S38-42.	0.1	0
167	A determination of topics for health technology assessment in Thailand: making decision makers involved. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2008, 91 Suppl 2, S100-9.	0.1	1
168	The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2008, 91 Suppl 2, S126-38.	0.1	4
169	Economic Evaluation of Treatment Administration Strategies of Ganciclovir for Cytomegalovirus Retinitis in HIV/AIDS Patients in Thailand. Pharmacoeconomics, 2007, 25, 413-428.	3.3	8
170	A Systematic Review of Economic Evaluation Literature in Thailand. Pharmacoeconomics, 2007, 25, 467-479.	3.3	57
171	Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand. Value in Health, 2007, 10, 61-72.	0.3	95
172	Is it worth offering a routine laparoscopic cholecystectomy in developing countries? A Thailand case study. Cost Effectiveness and Resource Allocation, 2005, 3, 10.	1.5	34
173	Cost-effectiveness of models for prevention of vertical HIV transmission - voluntary counseling and testing and choices of drug regimen. Cost Effectiveness and Resource Allocation, 2005, 3, 7.	1.5	23
174	Designing a reproductive health services package in the universal health insurance scheme in Thailand: match and mismatch of need, demand and supply. Health Policy and Planning, 2004, 19, i31-i39.	2.7	22
175	Health sector regulation in Thailand: recent progress and the future agenda. Health Policy, 2003, 63, 323-338.	3.0	39
176	Universal Coverage and Its Impact on Reproductive Health Services in Thailand. Reproductive Health Matters, 2002, 10, 59-69.	1.2	31
177	Pay-for-performance in resource-constrained settings: Lessons learned from Thailand's Quality and Outcomes Framework. F1000Research, 0, 5, 2700.	1.6	1
178	What is the value of explicit priority setting for health interventions? A simulation study. Health Care Management Science, 0, , .	2.6	1